Picture1.png
Autolus Therapeutics Announces Collaboration with Bristol Myers Squibb for Use of Autolus’ Proprietary Safety Switch System
October 04, 2022 07:00 ET | Autolus Therapeutics plc
- Bristol Myers Squibb to receive access to Autolus’ RQR8 safety switch for use in cell therapy programs - - Autolus to receive an upfront payment, with potential for near term option...
Singh360 Supports Crop One Holdings in Commissioning the World's Largest Vertical Farm
August 01, 2022 09:00 ET | Singh360 Inc.
MINNEAPOLIS, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Today, Singh360, a Minnesota-based provider of technologies and services to reduce energy consumption, announced that they partnered with Crop One...
Immatics and Bristol Myers Squibb Expand Strategic Alliance to Develop Gamma Delta Allogeneic Cell Therapy Programs
June 02, 2022 06:59 ET | https://immatics.com/
New multi-program collaboration to develop allogeneic TCR-T/CAR-T programs brings together Immatics’ allogeneic gamma delta T cell therapy platform ACTallo® with Bristol Myers Squibb’s technologies...
Immatics und Bristol Myers Squibb erweitern strategische Allianz zur Entwicklung allogener gamma-delta Zelltherapien
June 02, 2022 06:59 ET | Immatics N.V.
Neue Multi-Programm-Kollaboration zur Entwicklung allogener TCR-T/CAR-T-Programme kombiniert Immatics‘ allogene gamma-delta-T-Zell-basierte Zelltherapie-Plattform ACTallo® mit den Technologien und der...
Immatics Announces First Patient Treated with ACTengine® IMA203 TCR-T in Combination with Checkpoint Inhibitor Opdivo® (nivolumab) in Patients with Advanced Solid Tumors
May 18, 2022 07:00 ET | https://immatics.com/
The Phase 1b dose expansion cohort will evaluate safety, biological activity and initial anti-tumor activity of IMA203 TCR-T targeting PRAME in combination with nivolumab1, a PD-1 immune checkpoint...
Immatics behandelt ersten Patienten mit ACTengine® TCR-T-Zelltherapie IMA203 in Kombination mit Checkpoint-Inhibitor Opdivo® (Nivolumab) in Patienten mit fortgeschrittenen soliden Tumoren
May 18, 2022 07:00 ET | Immatics N.V.
Die Phase-1b-Dosis-Expansionskohorte untersucht die Sicherheit, biologische Aktivität und erste Anzeichen einer Anti-Tumor-Aktivität der IMA203 TCR-T-Zelltherapie gegen die Zielstruktur PRAME in...
Immatics Initiates Phase 1 Clinical Trial to Evaluate Lead TCR Bispecific IMA401 in Patients with Advanced Solid Tumors
May 10, 2022 07:00 ET | https://immatics.com/
Patient enrollment for IMA401 Phase 1 trial started at first clinical site in GermanyThe study will evaluate safety, tolerability, and initial anti-tumor activity of IMA401 in patients with recurrent...
Immatics beginnt klinische Phase-1-Studie zur Untersuchung des bispezifischen TCR-Kandidaten IMA401 bei Patienten mit fortgeschrittenen soliden Tumoren
May 10, 2022 07:00 ET | Immatics N.V.
Patientenrekrutierung für die Phase-1-Studie mit IMA401 hat an erstem klinischen Studienzentrum in Deutschland begonnenDie Studie untersucht die Sicherheit, Verträglichkeit und erste...
Visteon_wordmark_orange.jpg
Visteon Complements Industry-First Smart Wireless Battery Management System with Additional Electrification Technology
January 05, 2022 08:07 ET | Visteon Corporation
Intelligent Electrification Capability on Full Display at CES® 2022Electrification electronics designed to support global growth of electric vehiclesPower electronics capabilities beyond smartBMS...
22157.jpg
Global and China New Energy Vehicle VCU Market Report 2021: Under the New EEA, VCU Develops Towards Domain Control Integration
December 14, 2021 07:28 ET | Research and Markets
Dublin, Dec. 14, 2021 (GLOBE NEWSWIRE) -- The "Global and China New Energy Vehicle VCU Industry Report, 2021" report has been added to ResearchAndMarkets.com's offering. The VCU market size is...